203 related articles for article (PubMed ID: 35403837)
1. Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma.
Yu D; Li YF; Liang H; Wu JZ; Hu Y; Peng Y; Li TJ; Hou JF; Huang WJ; Guan LD; Han R; Xing YT; Zhang Y; Liu J; Feng L; Li CY; Liang XL; Ding YL; Zhou ZJ; Ji DM; Wang FF; Yu JH; Deng K; Xia DM; Dong DM; Hu HR; Liu YJ; Fu DX; He YL; Zhou DB; Yang HC; Jia R; Ke CW; Du T; Xie Y; Zhou R; Li CS; Wang ML; Yang XM
Adv Sci (Weinh); 2022 May; 9(14):e2104333. PubMed ID: 35403837
[TBL] [Abstract][Full Text] [Related]
2. Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
Díez JM; Romero C; Cruz M; Vandeberg P; Merritt WK; Pradenas E; Trinité B; Blanco J; Clotet B; Willis T; Gajardo R
J Infect Dis; 2022 Mar; 225(6):938-946. PubMed ID: 34693968
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
5. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
6. Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2-Characteristics of Intermediates and Final Product.
Lachert E; Lasocka J; Bielawski A; Sulkowska E; Guz K; Pyrc K; Dabrowska A; Wawryniuk-Malmon A; Letowska M; Tomasiewicz K; Grabarczyk P
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746798
[TBL] [Abstract][Full Text] [Related]
7. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
8. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
9. Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice.
Wong TY; Horspool AM; Russ BP; Ye C; Lee KS; Winters MT; Bevere JR; Miller OA; Rader NA; Cooper M; Kieffer T; Sourimant J; Greninger AL; Plemper RK; Denvir J; Cyphert HA; Barbier M; Torrelles JB; Martinez I; Martinez-Sobrido L; Damron FH
J Virol; 2022 Mar; 96(6):e0218421. PubMed ID: 35080423
[TBL] [Abstract][Full Text] [Related]
10. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
[TBL] [Abstract][Full Text] [Related]
11. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Jose Villar M; Rani Thimmiraju S; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez PJ; Elena Bottazzi M
Vaccine; 2022 Jun; 40(26):3655-3663. PubMed ID: 35568591
[TBL] [Abstract][Full Text] [Related]
12. Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2.
Burnouf T; Gathof B; Bloch EM; Bazin R; de Angelis V; Patidar GK; Rastvorceva RMG; Oreh A; Goel R; Rahimi-Levene N; Hindawi S; Al-Riyami AZ; So-Osman C;
Transfus Med Rev; 2022 Jul; 36(3):125-132. PubMed ID: 35879213
[TBL] [Abstract][Full Text] [Related]
13. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma and hyperimmune globulin therapy in COVID-19.
Cagdas D
Expert Rev Clin Immunol; 2021 Apr; 17(4):309-316. PubMed ID: 33620014
[No Abstract] [Full Text] [Related]
16. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
[TBL] [Abstract][Full Text] [Related]
17. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
18. Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations.
Karbiener M; Farcet MR; Schwaiger J; Powers N; Lenart J; Stewart JM; Tallman H; Kreil TR
J Infect Dis; 2021 Nov; 224(10):1707-1711. PubMed ID: 34543421
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
[TBL] [Abstract][Full Text] [Related]
20. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E; Zvi A; Alcalay R; Noy-Porat T; Peretz E; Mechaly A; Levy Y; Epstein E; Chitlaru T; Tennenhouse A; Aftalion M; Gur D; Paran N; Tamir H; Zimhony O; Weiss S; Mandelboim M; Mendelson E; Zuckerman N; Nemet I; Kliker L; Yitzhaki S; Shapira SC; Israely T; Fleishman SJ; Mazor O; Rosenfeld R
Cell Rep; 2021 Sep; 36(10):109679. PubMed ID: 34464610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
